[Clinical study and immunological observation on potenlini treatment of epidemic hemorrhage fever].
439 cases of epidemic hemorrhagic fever (EHF) in the febrile stage of the disease were randomly divided into two groups. 226 cases in therapeutic group were treated with daily intravenous drip of 60-100 ml potenlini for 3 days. Other measures of treatment in this group was just the same as those in the control group. The results showed that the duration of both the febrile stage and the hypotensive shock stage were shorter and the rate of recovering from hypotensive shock stage and oliguric stage in the therapeutic group (P less than 0.01) was higher as compared with the control group. BUN, ALT, urinary protein, white blood cells and platelets returned to normal level earlier than expected (P less than 0.01). The occurrence rate of complication and case fatality rate in therapeutic group were lower. The research showed that potenlini in the treatment of EHF has effects. But it has not remarkable effects on immune adjustment.
Xu
X T
XT
Liyi Medical School, Shandong.
Jing
P T
PT
Wang
C L
CL
D000293:Adolescent; D000328:Adult; D000917:Antibody Formation / Q000187:drug effects; D000998:Antiviral Agents; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D006480:Hemorrhagic Fever with Renal Syndrome / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D012397:Rosette Formation
D000998:Antiviral Agents; D004365:Drugs, Chinese Herbal